Institution Directory

Clinical trials at Johns Hopkins

Sites in Baltimore, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1429

Shown on this page

Current sort

Live official records

Conditions: Idiopathic Subglottic Stenosis
Interventions: Triamcinolone 0.1%, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Solid Tumors, CNS Tumors
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Any Advanced Solid Tumors
Interventions: Sarilumab, ICI Therapy; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Radiation-Induced Xerostomia and Hyposalivation
Interventions: RXRG001, Placebo; Biological
Lead sponsor: RiboX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more

Conditions: Lung Transplant Rejection
Interventions: Belumosudil, Azithromycin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions: Tirzepatide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Lung Diseases
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 35 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions: daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805, FOLFIRI regimen; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more

About this Johns Hopkins institution page

What this page lists: ClinicalTrials.gov records that list Johns Hopkins in Baltimore, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Johns Hopkins

Filter and sort this campus

Live official records

Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Tirzepatide for Treatment of CCCA

American Lung Association (ALA) Lung Health Cohort

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

About this Johns Hopkins institution page